CRISPR Cancer Breakthrough Gets Cautious Excitement
A Nature paper on CRISPR selectively destroying cancer cells, including so-called 'undruggable' cancers, landed on HN and the comments were cautiously optimistic. The memorable thread moment was someone saying they got excited about a cancer cure ten years ago, tried to share it with coworkers at lunch, and got laughed at. The implication: hype cycles in biotech have trained people to suppress excitement.
The most pointed comment was not about the science but about incentives: why does society allocate brilliant minds to adtech optimization when CRISPR cancer research exists? That is a values question with a structural answer (adtech pays better and faster) but it clearly struck a nerve.
This is a recurring HN theme: the gap between where technical talent is deployed and where it would do the most good. The difference today is that the concrete example (CRISPR vs. adtech) made it land harder than usual.
So what?
For founders in biotech or health, the sentiment is that the scientific community is making real progress on hard problems and the HN audience, usually skeptical, is paying attention. If you are building in this space, the credibility window for serious science is open right now in a way it has not always been.